查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971643

生物医学检测与分析服务市场：依检测类型、技术、检体类型、服务模式、检测方法、最终用户与应用划分－2026-2032年全球预测

Biomedical Testing & Analysis Services Market by Test Type, Technology, Sample Type, Service Model, Testing Method, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物医学检测和分析服务市场价值将达到 36.7 亿美元，到 2026 年将成长至 39.9 亿美元，到 2032 年将达到 66.5 亿美元，复合年增长率为 8.82%。

主要市场统计数据
基准年 2025 36.7亿美元
预计年份：2026年 39.9亿美元
预测年份 2032 66.5亿美元
复合年增长率 (%) 8.82%

为管理层提供的简明概述，清楚地总结了当前影响临床和研究环境中诊断测试和实验室分析能力的趋势。

生物医学检测和分析服务业正处于快速的科学技术进步、日益复杂的临床问题以及不断演变的医疗服务模式的交汇点。实验室和诊断服务提供者需要在临床化学、分子检测和次世代定序领域提供更高附加价值的见解，同时保持严格的品质标准和营运效率。同时，从医院网路到实验室等终端用户都期望获得更快的检测结果、更先进的分析能力以及与电子健康记录的整合。

对技术创新、自动化和混合服务模式如何重塑检查室能力和策略选择进行深入分析。

过去几年，变革性的变化重新定义了生物医学检测和分析服务的构思、组织和交付方式。高通量定序和数位PCR等分子技术的进步，使诊断从单标记检测转向多重检测和全基因组分析，从而能够更精准地进行疾病分层和标靶治疗选择。同时，质谱和流式细胞技术的改进拓展了表型分析和生物标记发现的能力，使检查室能够以更高的特异性和灵敏度解决复杂的临床问题。

对近期累积关税政策如何影响整个诊断侦测网路的采购决策、供应商风险和营运韧性进行详细评估。

政策制定者近期推出的关税措施，为整个诊断服务生态系统的采购、资金筹措和供应链规划带来了新的复杂性。试剂、耗材和设备的进口关税上调，并推高了实验室和服务供应商的直接投入成本。这种成本压力迫使许多机构重新评估其供应商组合，探索替代采购管道，并在某些情况下加快本地化策略，以降低进口波动风险。

基于全面细分的洞察阐明了测试类型、技术、最终用户需求和检体处理要求如何定义差异化的服务策略。

细分市场分析揭示了整个检测组合中不同的需求驱动因素和能力要求。就检测类型而言，临床化学检测仍然是常规诊断的基础，而血液学、免疫检测、微生物学和分子诊断检测则各自具有独特的基础设施、人员配备和品质保证要求。因此，实验室必须根据每种检测方法的特定处理能力和监管要求调整其技术专长。从技术角度来看，层析法、流式细胞技术、质谱、次世代定序和聚合酵素链锁反应(PCR) 等平台的应用场景各不相同，这会影响资本配置和验证路径，因此，领导者需要根据其临床和研究组合来优先考虑投资。

区域趋势和策略考量表明，美洲、欧洲、中东、非洲和亚太地区的市场正在开闢不同的营运和商业化道路。

区域趋势持续影响产业的竞争格局和营运模式。在美洲，活跃的临床试验活动、广泛的医院网路以及私人实验室的强劲需求，正推动着分子诊断和高通量平台的快速普及。该地区还拥有完善的报销系统和认证框架，这些都对服务设计、品质保证和商业化策略产生影响。同时，欧洲、中东和非洲地区呈现出多元化的格局，高水准的检测中心零星分布，而新兴市场则需要灵活、注重成本效益的部署模式和可扩展的培训项目，以扩大诊断服务的覆盖范围。

关键产业参与者、专业创新者和策略伙伴关係的评估状况，会全面影响竞争定位和客户选择标准。

竞争格局由大规模综合诊断公司、专业仪器製造商和灵活的合约实验室组成。成熟的跨国公司持续投资于平台创新、全球服务网络和全面的试剂产品组合，以支持临床检查室和研究机构。同时，专注于定序、质谱或免疫检测开发的专业公司凭藉差异化的性能特征、简化的工作流程和针对性的客户支持，正迅速崛起，吸引着高复杂度客户。

实验室经营团队和服务供应商可以实施的实用策略行动和韧性建设策略，以优化产能、确保供应稳定并提供临床价值。

产业领导者应采取能够保持营运柔软性并同时兼顾核心竞争力与市场机会的投资组合策略。首先，应优先投资于模组化自动化和可互操作系统，从而在不增加过多资本负担的情况下逐步扩大产能。这种方法可以降低技术过时的风险，并允许根据不断变化的临床需求快速调整工作流程。其次，应建构多元化的供应商策略，将与首选供应商的合作关係与替代采购方案结合，以降低关税和物流中断的影响。这包括探索建立区域製造伙伴关係和试剂联盟的可能性，以稳定供应并降低成本风险。

高度透明的研究框架，结合与关键相关人员的直接对话、对二手资料的综合分析和三角测量分析，确保了可操作和检验的见解。

本报告的调查方法结合了对检验部门负责人、采购经理和技术供应商的严谨初步访谈，以及对公开技术文献、监管指南和行业白皮书的全面二手资料研究。初步访谈包括结构化访谈和业务流程现场观察，旨在了解不同临床和研究环境中的实际流程、挑战和策略重点。二级资讯来源提供了对技术能力、检验要求和以往实施模式的背景理解。

策略整合强调了透过协调技术能力、营运柔软性和伙伴关係主导能力来维持诊断领域领导地位的必要性。

生物医学检测和分析服务的未来将取决于高解析度诊断、整合资讯学和营运韧性的持续进步。能够将技术投资与明确的临床和商业应用场景进行策略性结合的实验室和服务供应商将获得竞争优势。同时，供应链的波动性、不断变化的关税体係以及各地区的不同需求，都要求企业制定灵活的筹资策略和扩充性的服务模式，以应对突发衝击和不断变化的需求模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依检测类型分類的生物医学检测与分析服务市场

  • 临床化学
  • 血液学
  • 免疫检测
  • 微生物学
  • 分子诊断

第九章：生物医学检测与分析服务市场：依技术划分

  • 层析法
  • 流式细胞技术
  • 质谱分析
  • 次世代定序
  • 聚合酵素链锁反应

第十章：依检体类型分類的生物医学检测与分析服务市场

  • 血
  • 唾液
  • 组织
  • 尿

第十一章：按服务模式分類的生物医学检测与分析服务市场

  • 内部
  • 外包

第十二章：依检测方法分類的生物医学检测与分析服务市场

  • 定性
  • 定量

第十三章：生物医学检测与分析服务市场：依最终用户划分

  • 诊断中心
  • 医院和诊所
  • 製药公司
  • 研究所

第十四章 生物医学检测与分析服务市场：依应用领域划分

  • 疾病诊断
  • 药物研发
  • 基因检测
  • 毒理学

第十五章：生物医学检测与分析服务市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：生物医学检测与分析服务市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 生物医学检测与分析服务市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国生物医学检测与分析服务市场

第十九章：中国生物医学检测分析服务市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • ICON plc
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • North American Science Associates LLC
  • Quest Diagnostics Incorporated
  • SGS SA
  • Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-2B5802CFE404

The Biomedical Testing & Analysis Services Market was valued at USD 3.67 billion in 2025 and is projected to grow to USD 3.99 billion in 2026, with a CAGR of 8.82%, reaching USD 6.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.67 billion
Estimated Year [2026] USD 3.99 billion
Forecast Year [2032] USD 6.65 billion
CAGR (%) 8.82%

A concise executive orientation that crystallizes the current forces shaping diagnostic testing and laboratory analysis capabilities across clinical and research environments

The biomedical testing and analysis services sector sits at the confluence of rapid scientific progress, increasing clinical complexity, and evolving healthcare delivery models. Laboratories and diagnostic providers are being asked to deliver higher-value insights across clinical chemistry, molecular assays, and next-generation sequencing while maintaining rigorous quality standards and operational efficiency. At the same time, end users from hospital networks to research laboratories expect faster turnaround, enhanced analytics, and integration with digital health records.

This environment is shaped by continuous technological innovation, rising clinical demand for personalized medicine, and pressures to optimize cost and throughput. Consequently, leaders within academic, clinical, and commercial laboratories are recalibrating investments in automation, informatics, and talent to preserve competitiveness. The objective of this executive summary is to synthesize the key dynamics affecting diagnostic service delivery, illuminate structural shifts that will define near-term strategy, and provide an actionable framework for stakeholders seeking to align capabilities with emerging clinical and commercial requirements.

An incisive synthesis of how technological advancements, automation, and hybrid service models are reshaping laboratory capabilities and strategic choices

Over the past several years, transformative shifts have redefined how biomedical testing and analysis services are conceived, organized, and delivered. Advances in molecular techniques such as high-throughput sequencing and digital PCR have moved diagnostics from single-marker assays toward multiplexed and genomic-scale interrogations, enabling more precise disease stratification and targeted therapeutic selection. In parallel, improvements in mass spectrometry and flow cytometry have expanded phenotyping and biomarker discovery capabilities, allowing laboratories to address complex clinical questions with greater specificity and sensitivity.

Operationally, automation and laboratory information management systems are converging with artificial intelligence and machine learning to streamline workflows, reduce manual error, and accelerate result interpretation. These technology-driven gains are complemented by an increasing reliance on hybrid service models where in-house capacity is augmented by specialized outsourced providers for high-complexity or low-volume assays. As a result, organizations must now balance investments in core infrastructure with strategic partnerships that preserve flexibility while meeting evolving regulatory, reimbursement, and quality requirements. Together, these shifts demand a reimagined strategic playbook for diagnostic leaders seeking to capture clinical value and operational resilience.

A detailed appraisal of how recent cumulative tariff policies are influencing procurement decisions, supplier risk, and operational resilience across diagnostic testing networks

Recent tariff actions implemented by policymakers have introduced a new layer of complexity for procurement, capital acquisition, and supply chain planning across the diagnostic services ecosystem. Increases in import duties on reagents, consumables, and instrumentation have elevated direct input costs for laboratories and testing service providers. This cost pressure has prompted many organizations to reassess supplier portfolios, seek alternative sourcing corridors, and, in some instances, accelerate localization strategies to mitigate exposure to import volatility.

Beyond direct cost effects, tariffs have influenced vendor contracting behaviors and lead-time expectations, prompting some manufacturers to reconfigure distribution networks or prioritize shipments in response to shifting demand. For laboratory operators, the cumulative effect has been a reinterpretation of inventory policies, a renewed focus on supplier risk assessment, and a drive to rationalize instrument footprints to concentrate high-throughput testing on the most cost-effective platforms. Importantly, these dynamics have also catalyzed negotiations with commercial partners over pricing, rebate structures, and service terms, as buyers pursue predictable total cost of ownership while preserving quality and compliance standards.

Comprehensive segmentation-driven insights that clarify how test types, technologies, end-user needs, and sample handling requirements define differentiated service strategies

Segmentation insights reveal differentiated demand drivers and capability requirements across testing portfolios. When considering test type differentiation, clinical chemistry remains foundational for routine diagnostics while hematology, immunoassay, microbiology, and molecular diagnostics each impose discrete infrastructure, staffing, and quality assurance demands; laboratories must therefore match technical competencies to the unique throughput and regulatory profiles of each modality. From a technology perspective, platforms such as chromatography, flow cytometry, mass spectrometry, next-generation sequencing, and polymerase chain reaction occupy distinct use cases that influence capital allocation and validation pathways, requiring leaders to prioritize investments that align with their clinical and research mix.

End user segmentation underscores varied service expectations: diagnostic centers prioritize throughput and cost efficiency, hospitals and clinics balance rapid turnaround with integration into clinical workflows, pharmaceutical companies demand rigorous traceability and compliance for trial support, and research laboratories emphasize flexibility and innovation adoption. Application-based distinctions further refine requirements, as disease diagnosis, drug development, genetic testing, and toxicology each demand different sensitivity, specificity, and reporting capabilities. Sample type considerations are material in operational planning because blood, saliva, tissue, and urine each require unique pre-analytic handling and storage protocols that affect supply chains and test validity. Service model choices between in-house and outsourced arrangements determine control over quality and cost, while testing method classification into qualitative and quantitative formats impacts validation approaches, regulatory submissions, and downstream analytics. Integrating these segmentation layers helps stakeholders design services that meet end-user expectations while managing cost, compliance, and scalability.

Regional dynamics and strategic considerations that illustrate how the Americas, Europe Middle East & Africa, and Asia-Pacific markets shape distinct operational and commercialization pathways

Regional dynamics continue to shape the competitive and operational contours of the industry. In the Americas, robust clinical trial activity, expansive hospital networks, and strong private-laboratory demand drive sophisticated adoption of molecular and high-throughput platforms. This region also exhibits advanced reimbursement ecosystems and established accreditation frameworks, which influence service design, quality assurance, and commercialization strategies. In contrast, the Europe, Middle East & Africa region presents a heterogeneous landscape where pockets of high-capability centers coexist with emerging markets that require adaptable, cost-conscious deployment models and scalable training programs to expand diagnostic reach.

The Asia-Pacific region is notable for rapid capacity expansion, significant public and private investments in genomics and molecular diagnostics, and an active manufacturing base for reagents and devices. These factors collectively create a dynamic environment where technology adoption can accelerate but is accompanied by diverse regulatory and reimbursement pathways. Cross-region operational strategies must therefore account for differences in clinical practice patterns, supply chain linkages, and talent availability, while exploiting opportunities for regional centers of excellence to support neighboring markets and enable economies of scale in high-complexity testing.

An evaluative landscape of major industry participants, specialist innovators, and strategic partnerships that collectively influence competitive positioning and client selection criteria

Competitive landscapes are driven by a mix of large integrated diagnostics corporations, specialized instrument manufacturers, and nimble contract testing organizations. Established multinational firms continue to invest in platform innovation, global service networks, and comprehensive reagent portfolios to support clinical laboratories and research institutions. At the same time, specialist companies focused on sequencing, mass spectrometry, or immunoassay development are gaining traction by delivering differentiated performance characteristics, streamlined workflows, and targeted customer support that appeal to high-complexity customers.

Contract research organizations and laboratory outsourcing partners are expanding their service breadth to capture specialized assay volumes and provide clients with end-to-end project management, from sample logistics to data analytics. Strategic collaborations between diagnostic providers, technology vendors, and clinical stakeholders are increasingly important for accelerating validation timelines and expanding test menus. For buyers, vendor selection now involves evaluating not just analytical performance but also post-sales support, instrument uptime guarantees, regulatory assistance, and the flexibility to adapt service models to fluctuating clinical demand.

Practical strategic actions and resilience-building measures that laboratory executives and service providers can implement to optimize capability, supply stability, and clinical value delivery

Industry leaders should pursue a portfolio strategy that aligns core competencies with market opportunities while preserving operational flexibility. First, prioritize investments in modular automation and interoperable informatics that allow incremental capacity scaling without prohibitive capital burdens. This approach reduces the risk of technology obsolescence and enables rapid reconfiguration of workflows as clinical priorities shift. Next, develop diversified supplier strategies that combine preferred vendor relationships with secondary sourcing options to mitigate tariff and logistics disruptions; this includes exploring regional manufacturing partnerships or reagent consortia to stabilize supply and cost exposure.

Leaders should also formalize collaborative arrangements with specialized testing partners to manage episodic demand for niche assays and to accelerate access to new capabilities. Concurrently, invest in workforce development programs that upskill laboratory personnel in molecular techniques, data analytics, and quality management to sustain high-performance operations. Finally, integrate value-based metrics into contractual arrangements and internal KPIs, emphasizing turnaround reliability, analytic accuracy, and clinical impact to guide continuous improvement and demonstrate the return on diagnostic investments.

A transparent research framework that integrates primary stakeholder engagement, secondary literature synthesis, and triangulated analysis to ensure actionable and validated insights

The research approach for this report combined rigorous primary engagement with laboratory leaders, procurement managers, and technology vendors alongside comprehensive secondary research into published technical literature, regulatory guidance, and industry white papers. Primary interactions included structured interviews and operational walkthroughs to capture real-world process flows, pain points, and strategic priorities across diverse clinical and research settings. Secondary sources informed the contextual understanding of technological capabilities, validation requirements, and historical adoption patterns.

Data synthesis employed triangulation across qualitative insights and documented evidence to ensure robustness of conclusions. Analytical steps included mapping technology use cases to end-user requirements, evaluating supplier ecosystems for resilience factors, and assessing regional nuances in regulatory and reimbursement environments. Quality assurance for the research included cross-validation of key findings with subject-matter experts and review against contemporary peer-reviewed and regulatory publications to maintain accuracy and relevance for decision-makers.

A strategic synthesis that reinforces the imperative for alignment between technical capability, operational flexibility, and partnership-driven capacity to sustain diagnostic leadership

The trajectory of biomedical testing and analysis services is defined by a persistent push toward higher-resolution diagnostics, integrated informatics, and operational resilience. Laboratories and testing service providers that strategically align technology investments with clearly defined clinical and commercial use cases will secure competitive advantage. At the same time, supply chain volatility, shifting tariff regimes, and heterogeneous regional requirements necessitate flexible sourcing strategies and scalable service models that can adapt to episodic shocks and evolving demand patterns.

Ultimately, success will depend on the ability to combine technical excellence with pragmatic operational design: validating high-performance platforms, ensuring robust sample management, cultivating cross-disciplinary talent, and forging partnerships that extend capacity without undermining quality. By taking a deliberate, segmentation-aware approach to capability development and regional deployment, organizations can better position themselves to deliver reliable, clinically meaningful testing services that support patient care and research progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biomedical Testing & Analysis Services Market, by Test Type

  • 8.1. Clinical Chemistry
  • 8.2. Hematology
  • 8.3. Immunoassay
  • 8.4. Microbiology
  • 8.5. Molecular Diagnostics

9. Biomedical Testing & Analysis Services Market, by Technology

  • 9.1. Chromatography
  • 9.2. Flow Cytometry
  • 9.3. Mass Spectrometry
  • 9.4. Next Generation Sequencing
  • 9.5. Polymerase Chain Reaction

10. Biomedical Testing & Analysis Services Market, by Sample Type

  • 10.1. Blood
  • 10.2. Saliva
  • 10.3. Tissue
  • 10.4. Urine

11. Biomedical Testing & Analysis Services Market, by Service Model

  • 11.1. In-House
  • 11.2. Outsourced

12. Biomedical Testing & Analysis Services Market, by Testing Method

  • 12.1. Qualitative
  • 12.2. Quantitative

13. Biomedical Testing & Analysis Services Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Hospitals And Clinics
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Laboratories

14. Biomedical Testing & Analysis Services Market, by Application

  • 14.1. Disease Diagnosis
  • 14.2. Drug Development
  • 14.3. Genetic Testing
  • 14.4. Toxicology

15. Biomedical Testing & Analysis Services Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Biomedical Testing & Analysis Services Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Biomedical Testing & Analysis Services Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Biomedical Testing & Analysis Services Market

19. China Biomedical Testing & Analysis Services Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Charles River Laboratories International, Inc.
  • 20.6. Danaher Corporation
  • 20.7. Eurofins Scientific SE
  • 20.8. ICON plc
  • 20.9. IQVIA Holdings Inc.
  • 20.10. Laboratory Corporation of America Holdings
  • 20.11. North American Science Associates LLC
  • 20.12. Quest Diagnostics Incorporated
  • 20.13. SGS SA
  • 20.14. Thermo Fisher Scientific Inc.
  • 20.15. Thermo Fisher Scientific Inc.
  • 20.16. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY OUTSOURCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY OUTSOURCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 166. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 190. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 191. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 199. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA BIOMEDICAL TESTING & ANALYSIS SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)